Mayor Chuck Reed recognizes contribution to city and children with rare
SAN JOSE, Calif., July 7 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today the receipt of a commendation from the City of San Jose, acknowledging the company's contributions in fighting rare childhood diseases. The commendation recognizes "Edison for outstanding achievements in developing drugs for unmet medical need, and its commitment to public-private partnership, and extend our best wishes for many years of success in positively impacting the lives of children and individuals with mitochondrial diseases in America and throughout the world."
Mayor Chuck Reed and Councilmember Forrest Williams presented the commendation to Edison Chairman and CEO, Dr. Guy Miller on February 12th, 2008 at City Hall. "Since starting operations at the San Jose BioCenter in January 2006, Edison Pharmaceuticals has helped to make San Jose a center of life science technology. Edison is doing a remarkable job by focusing its R&D efforts on discovering a treatment for mitochondrial diseases -- that impair energy metabolism, and for which there exist no drugs," said Mayor Chuck Reed. "I congratulate Edison on achieving high performance standards and for the commitment of its founder Dr. Guy Miller and his team to improving the lives of children throughout the world."
About Edison Pharmaceuticals
Edison Pharmaceuticals, Inc., a biotechnology company based in Silicon Valley California at the San Jose Biocenter, is focused on developing drugs for rare diseases that impair energy metabolism. Edison possesses a technology platform and specialized knowledge in redox therapeutics -- pivotal to targeting genetic defects in the mitochondria. The Company's initial focus is on inherited diseases of the mitochondrial respiratory chain. The company is leveraging insights derived from those studies to pursue other diseases that share common mechanisms, such as Huntington's disease and diseases of aging. Edison has obtained substantial peer-reviewed grants from multiple foundations and the National Institutes of Health.
|SOURCE Edison Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved